Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is a commercial-stage biotechnology company with a strong portfolio of drug candidates targeting multiple therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. Its flagship product, KIMMTRAK, has shown significant survival benefits in clinical trials and has high market penetration. With multiple upcoming catalysts, including late-stage readouts and potential label expansions, Immunocore has a strong outlook for growth in the coming years. Risks include clinical development, competition, and commercialization uncertainties, but a risk-adjusted DCF and SOTP-based analysis yields a firm value of approximately $5 billion or a possible $100 price target.

Bears say

Immunocore Holdings is facing potential market competition, as IDEAYA's program for HLA-A*02:01-negative patients may be able to treat the entire population of mUM and offers more flexibility in the longer term. Additionally, the company's financials show a need for additional funds, and there is no guarantee of obtaining favorable financing. Although KIMMTRAK has shown promising results, the company faces uncertainties in maintaining its market position and financial stability.

Immunocore Holdings (IMCR) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 8 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.